1	Interview	_	_	NN	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	Reggie	_	_	NNP	_	_	_	_	_
4	Bibbs	_	_	NNP	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	his	_	_	PRP$	_	_	_	_	_
7	life	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	neurofibromatosis	_	_	NN	_	_	_	_	_


1	Friday	_	_	NNP	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	December	_	_	NNP	_	_	_	_	_
4	14	_	_	CD	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	2007	_	_	CD	_	_	_	_	_


1	Infobox	_	_	NN	_	_	_	_	_
2	:	_	_	:	_	_	_	_	_
3	What	_	_	WP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	neurofibromatosis	_	_	NN	_	_	_	_	_
6	?	_	_	.	_	_	_	_	_


1	Neurofibromatosis	_	_	NN	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	NF	_	_	NN	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	genetic	_	_	JJ	_	_	_	_	_
8	condition	_	_	NN	_	_	_	_	_
9	causing	_	_	VBG	_	_	_	_	_
10	benign	_	_	JJ	_	_	_	_	_
11	tumors	_	_	NNS	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	neurofibromas	_	_	NNS	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	grow	_	_	VB	_	_	_	_	_
17	along	_	_	IN	_	_	_	_	_
18	certain	_	_	JJ	_	_	_	_	_
19	types	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	nerves	_	_	NNS	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	addition	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	it	_	_	PRP	_	_	_	_	_
28	can	_	_	MD	_	_	_	_	_
29	affect	_	_	VB	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	development	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	bones	_	_	NNS	_	_	_	_	_
34	or	_	_	CC	_	_	_	_	_
35	skin	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	variants	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	disease	_	_	NN	_	_	_	_	_
8	but	_	_	CC	_	_	_	_	_
9	type	_	_	NN	_	_	_	_	_
10	1	_	_	CD	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	type	_	_	NN	_	_	_	_	_
13	2	_	_	CD	_	_	_	_	_
14	NF	_	_	NN	_	_	_	_	_
15	account	_	_	VBP	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	vast	_	_	JJ	_	_	_	_	_
19	majority	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	cases	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	disease	_	_	NN	_	_	_	_	_
3	manifestations	_	_	NNS	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	vary	_	_	VB	_	_	_	_	_
6	from	_	_	IN	_	_	_	_	_
7	very	_	_	RB	_	_	_	_	_
8	mild	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	severe	_	_	JJ	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Major	_	_	JJ	_	_	_	_	_
2	symptoms	_	_	NNS	_	_	_	_	_
3	include	_	_	VBP	_	_	_	_	_
4	growths	_	_	NNS	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	under	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	skin	_	_	NN	_	_	_	_	_
10	;	_	_	:	_	_	_	_	_
11	skin	_	_	NN	_	_	_	_	_
12	pigmentations	_	_	NNS	_	_	_	_	_
13	called	_	_	VBN	_	_	_	_	_
14	café	_	_	NN	_	_	_	_	_
15	au	_	_	NN	_	_	_	_	_
16	lait	_	_	NN	_	_	_	_	_
17	spots	_	_	NNS	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	type	_	_	NN	_	_	_	_	_
20	1	_	_	CD	_	_	_	_	_
21	;	_	_	:	_	_	_	_	_
22	acoustic	_	_	JJ	_	_	_	_	_
23	nerve	_	_	NN	_	_	_	_	_
24	tumors	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	consequent	_	_	JJ	_	_	_	_	_
27	hearing	_	_	NN	_	_	_	_	_
28	loss	_	_	NN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	type	_	_	NN	_	_	_	_	_
31	2	_	_	CD	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Growths	_	_	NNS	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	affect	_	_	VB	_	_	_	_	_
4	nearly	_	_	RB	_	_	_	_	_
5	all	_	_	DT	_	_	_	_	_
6	parts	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	body	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	pressure	_	_	NN	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	nearby	_	_	JJ	_	_	_	_	_
15	structures	_	_	NNS	_	_	_	_	_
16	can	_	_	MD	_	_	_	_	_
17	cause	_	_	VB	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	wide	_	_	JJ	_	_	_	_	_
20	variety	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	complications	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	small	_	_	JJ	_	_	_	_	_
5	risk	_	_	NN	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	tumors	_	_	NNS	_	_	_	_	_
9	transform	_	_	VBP	_	_	_	_	_
10	into	_	_	IN	_	_	_	_	_
11	malignant	_	_	JJ	_	_	_	_	_
12	cancerous	_	_	JJ	_	_	_	_	_
13	lesions	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	NF	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	one	_	_	CD	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	most	_	_	RBS	_	_	_	_	_
7	common	_	_	JJ	_	_	_	_	_
8	single-gene	_	_	JJ	_	_	_	_	_
9	human	_	_	JJ	_	_	_	_	_
10	diseases	_	_	NNS	_	_	_	_	_
11	;	_	_	:	_	_	_	_	_
12	around	_	_	RB	_	_	_	_	_
13	1	_	_	CD	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	2,500-4,000	_	_	CD	_	_	_	_	_
16	live	_	_	JJ	_	_	_	_	_
17	births	_	_	NNS	_	_	_	_	_
18	are	_	_	VBP	_	_	_	_	_
19	affected	_	_	VBN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	NF-1	_	_	NNP	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	whereas	_	_	IN	_	_	_	_	_
24	NF-2	_	_	NNP	_	_	_	_	_
25	occurs	_	_	VBZ	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	about	_	_	RB	_	_	_	_	_
28	1	_	_	CD	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	50,000-120,000	_	_	CD	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Both	_	_	DT	_	_	_	_	_
2	type	_	_	NN	_	_	_	_	_
3	1	_	_	CD	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	2	_	_	CD	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	autosomal	_	_	JJ	_	_	_	_	_
8	dominant	_	_	JJ	_	_	_	_	_
9	conditions	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	meaning	_	_	VBG	_	_	_	_	_
12	that	_	_	IN	_	_	_	_	_
13	only	_	_	RB	_	_	_	_	_
14	one	_	_	CD	_	_	_	_	_
15	copy	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	mutated	_	_	VBN	_	_	_	_	_
19	gene	_	_	NN	_	_	_	_	_
20	need	_	_	MD	_	_	_	_	_
21	be	_	_	VB	_	_	_	_	_
22	inherited	_	_	VBN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	pass	_	_	VB	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	disorder	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	child	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	parent	_	_	NN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	neurofibromatosis	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	unaffected	_	_	JJ	_	_	_	_	_
11	parent	_	_	NN	_	_	_	_	_
12	will	_	_	MD	_	_	_	_	_
13	have	_	_	VB	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	50	_	_	CD	_	_	_	_	_
16	%	_	_	NN	_	_	_	_	_
17	chance	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	inheriting	_	_	VBG	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	disorder	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	gene	_	_	NN	_	_	_	_	_
3	responsible	_	_	JJ	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	NF-1	_	_	NNP	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	possibly	_	_	RB	_	_	_	_	_
8	NF-2	_	_	NNP	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	thought	_	_	VBN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	function	_	_	VB	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	tumor	_	_	NN	_	_	_	_	_
16	suppressor	_	_	NN	_	_	_	_	_
17	gene	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	most	_	_	JJS	_	_	_	_	_
3	cases	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	neurofibromatosis	_	_	NN	_	_	_	_	_
6	1	_	_	CD	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	patients	_	_	NNS	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	live	_	_	VB	_	_	_	_	_
11	normal	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	productive	_	_	JJ	_	_	_	_	_
14	lives	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	about	_	_	RB	_	_	_	_	_
3	25-40	_	_	CD	_	_	_	_	_
4	%	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	there	_	_	EX	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	associated	_	_	VBN	_	_	_	_	_
11	learning	_	_	NN	_	_	_	_	_
12	disability	_	_	NN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	without	_	_	IN	_	_	_	_	_
16	ADHD	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	some	_	_	DT	_	_	_	_	_
3	cases	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	neurofibromatosis	_	_	NN	_	_	_	_	_
6	2	_	_	CD	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	damage	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	nearby	_	_	JJ	_	_	_	_	_
12	vital	_	_	JJ	_	_	_	_	_
13	structures	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	such	_	_	JJ	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	cranial	_	_	JJ	_	_	_	_	_
19	nerves	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	brainstem	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	can	_	_	MD	_	_	_	_	_
25	be	_	_	VB	_	_	_	_	_
26	life-threatening	_	_	JJ	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	When	_	_	WRB	_	_	_	_	_
2	tumors	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	causing	_	_	VBG	_	_	_	_	_
5	pain	_	_	NN	_	_	_	_	_
6	or	_	_	CC	_	_	_	_	_
7	disfiguration	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	surgery	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	thus	_	_	RB	_	_	_	_	_
12	far	_	_	RB	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	only	_	_	RB	_	_	_	_	_
15	proven	_	_	VBN	_	_	_	_	_
16	beneficial	_	_	JJ	_	_	_	_	_
17	treatment	_	_	NN	_	_	_	_	_
18	option	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Reggie	_	_	NNP	_	_	_	_	_
2	Bibbs	_	_	NNP	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	43-year-old-man	_	_	NN	_	_	_	_	_
6	living	_	_	VBG	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	Houston	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	Texas	_	_	NNP	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Mr	_	_	NNP	_	_	_	_	_
2	Bibbs	_	_	NNP	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	born	_	_	VBN	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	genetic	_	_	JJ	_	_	_	_	_
8	disease	_	_	NN	_	_	_	_	_
9	called	_	_	VBN	_	_	_	_	_
10	neurofibromatosis	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	NF	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	causes	_	_	VBZ	_	_	_	_	_
17	him	_	_	PRP	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	develop	_	_	VB	_	_	_	_	_
20	tumors	_	_	NNS	_	_	_	_	_
21	on	_	_	IN	_	_	_	_	_
22	his	_	_	PRP$	_	_	_	_	_
23	body	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	see	_	_	VB	_	_	_	_	_
26	infobox	_	_	NN	_	_	_	_	_
27	on	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	right	_	_	NN	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	NF	_	_	NNP	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	subtle	_	_	JJ	_	_	_	_	_
6	disease	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	but	_	_	CC	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	Bibbs	_	_	NNP	_	_	_	_	_
11	'	_	_	POS	_	_	_	_	_
12	case	_	_	NN	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	has	_	_	VBZ	_	_	_	_	_
15	left	_	_	VBN	_	_	_	_	_
16	him	_	_	PRP	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	disfigured	_	_	VBN	_	_	_	_	_
20	face	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	deformed	_	_	JJ	_	_	_	_	_
23	leg	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	But	_	_	CC	_	_	_	_	_
2	he	_	_	PRP	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	happy	_	_	JJ	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	way	_	_	NN	_	_	_	_	_
8	he	_	_	PRP	_	_	_	_	_
9	looks	_	_	VBZ	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	does	_	_	VBZ	_	_	_	_	_
13	n't	_	_	RB	_	_	_	_	_
14	want	_	_	VB	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	change	_	_	VB	_	_	_	_	_
17	his	_	_	PRP$	_	_	_	_	_
18	appearance	_	_	NN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	please	_	_	VB	_	_	_	_	_
21	other	_	_	JJ	_	_	_	_	_
22	people	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	He	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	launched	_	_	VBN	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	successful	_	_	JJ	_	_	_	_	_
6	campaign	_	_	NN	_	_	_	_	_
7	entitled	_	_	VBN	_	_	_	_	_
8	"	_	_	``	_	_	_	_	_
9	Just	_	_	RB	_	_	_	_	_
10	Ask	_	_	VB	_	_	_	_	_
11	"	_	_	''	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	that	_	_	DT	_	_	_	_	_
15	's	_	_	VBZ	_	_	_	_	_
16	just	_	_	RB	_	_	_	_	_
17	what	_	_	WP	_	_	_	_	_
18	Wikinews	_	_	NNP	_	_	_	_	_
19	did	_	_	VBD	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	video-interview	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	interview	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	prepared	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	Wikinews	_	_	NNP	_	_	_	_	_
7	reporter	_	_	NN	_	_	_	_	_
8	Michaël	_	_	NNP	_	_	_	_	_
9	Laurent	_	_	NNP	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	help	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	Bertalan	_	_	NNP	_	_	_	_	_
15	Meskó	_	_	NNP	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	who	_	_	WP	_	_	_	_	_
18	has	_	_	VBZ	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	popular	_	_	JJ	_	_	_	_	_
21	genetics	_	_	NNS	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	web	_	_	NN	_	_	_	_	_
24	2.0	_	_	CD	_	_	_	_	_
25	blog	_	_	NN	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Their	_	_	PRP$	_	_	_	_	_
2	questions	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	sent	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	close	_	_	JJ	_	_	_	_	_
8	friend	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	Mr.	_	_	NNP	_	_	_	_	_
11	Bibbs	_	_	NNP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	Lou	_	_	NNP	_	_	_	_	_
14	Congelio	_	_	NNP	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	who	_	_	WP	_	_	_	_	_
17	kindly	_	_	RB	_	_	_	_	_
18	conducted	_	_	VBD	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	interview	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	interview	_	_	NN	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	neurofibromatosis	_	_	NN	_	_	_	_	_


1	Reggie	_	_	NNP	_	_	_	_	_
2	Bibbs	_	_	NNP	_	_	_	_	_


1	:	_	_	:	_	_	_	_	_
2	My	_	_	PRP$	_	_	_	_	_
3	name	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	Reggie	_	_	NNP	_	_	_	_	_
6	Bibbs	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	I	_	_	PRP	_	_	_	_	_
9	am	_	_	VBP	_	_	_	_	_
10	43	_	_	CD	_	_	_	_	_
11	years	_	_	NNS	_	_	_	_	_
12	old	_	_	JJ	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	I	_	_	PRP	_	_	_	_	_
15	live	_	_	VBP	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	Houston	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	Texas	_	_	NNP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Wikinews	_	_	NNP	_	_	_	_	_
2	:	_	_	:	_	_	_	_	_
3	Can	_	_	MD	_	_	_	_	_
4	you	_	_	PRP	_	_	_	_	_
5	explain	_	_	VB	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	our	_	_	PRP$	_	_	_	_	_
8	readers	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	simple	_	_	JJ	_	_	_	_	_
11	terms	_	_	NNS	_	_	_	_	_
12	what	_	_	WP	_	_	_	_	_
13	exactly	_	_	RB	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	neurofibromatosis	_	_	NN	_	_	_	_	_
16	?	_	_	.	_	_	_	_	_

